Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Ross

Neurological Surgery Warrenville, IL Medical Doctor

NPI 1316034010 CMS profile 150487

3S220 Warren Ave, Warrenville, IL 60555

Open in the dashboard

General payments

$1,657

33 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Ross of Warrenville, IL is reported in the CMS Open Payments database as having received $1,657 across 33 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $276 7
2024 General $348 4
2023 General $125 4
2022 General $262 3
2021 General $560 9
2020 General $63 4
2019 General $23 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Ross
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Matthew Ross were reported at $276. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Matthew Ross Neurological Surgery median Middle half National median
2019 $23 $582 $138–$3,006 $163
2020 $63 $294 $76–$2,174 $114
2021 $560 $387 $105–$2,432 $132
2022 $262 $542 $139–$2,989 $149
2023 $125 $534 $145–$2,697 $160
2024 $348 $574 $155–$3,046 $164
2025 $276 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimvie Inc. $380 3 payments
  2. Kuros Biosciences USA, Inc $361 5 payments
  3. Abbott Laboratories $164 1 payment
  4. Boston Scientific Corporation $154 2 payments
  5. Nevro Corp. $150 1 payment
  6. DePuy Synthes Sales Inc. $115 6 payments
  7. SI-BONE, Inc. $89 4 payments
  8. Providence Medical Technology, Inc. $62 1 payment
  9. Stryker Corporation $60 4 payments
  10. Intrinsic Therapeutics $40 1 payment
  11. Other $82 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,657 33 payments
Products named General payments · program years 2019–2025
  1. Proclaim DRG IPG $164 1 payment
  2. Senza $150 1 payment
  3. WaveWriter Alpha Prime 16 $144 1 payment
  4. Mobi-C $141 1 payment
  5. Biomet SpinalPak Non-invasive Spine Fusion Stimulator System $128 1 payment
  6. SpF XL IIb Implantable Spinal Fusion Stimulator $111 1 payment
  7. IFUSE IMPLANT $49 3 payments
  8. BARRICAID ACD (ANNULAR CLOSURE DEVICE) Annular Closure Device $40 1 payment
  9. BARRICAID ACD (ANNULAR CLOSURE DEVICE) Annular Closure Device $40 1 payment
  10. MAGNETOS $40 1 payment
  11. Other $378 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

639

Median for Neurosurgery: 83

Drug cost

$5,143

Median for Neurosurgery: $872

Branded share of claims

12.5%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 98 $1,108
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 65 $867
Meloxicam Generic 111 $592
Cyclobenzaprine Hcl Generic 63 $576
Methylprednisolone Generic 87 $417
Butalbital-Acetaminophen-Caffe Butalb/Acetaminophen/Caffeine Brand 15 $408
Pregabalin Generic 18 $406
Tramadol Hcl Generic 98 $280
Baclofen Generic 30 $236
Diclofenac Sodium Generic 17 $92

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$111,760

Medicare's payments for the services billed

Medicare patients

267

Average age 75

Services billed

704

127 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 27%
Diabetes 22%
Cancer 22%
Depression 19%
Chronic kidney disease 18%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

33 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record